Fudan Tinnitus Doctor for Tinnitus Management
A Multi-agent Large Language Model Conversational AI for Tinnitus Management: The Fudan Tinnitus Doctor Randomized Controlled Trial
The goal of this clinical trial is to evaluate whether a conversational artificial intelligence-based digital intervention can improve symptoms in adults with chronic subjective tinnitus.
The main questions it aims to answer are:
Does the Fudan Tinnitus Doctor (FTD) system reduce tinnitus severity as measured by the Tinnitus Handicap Inventory (THI).
Does the FTD system improve sleep quality, anxiety, depression, and overall patient-reported outcomes.
Researchers will compare the FTD system to a non-conversational digital education program to determine whether the AI-based intervention provides greater clinical benefits.
Participants will:
Use either the FTD conversational AI system or a static digital education program for 30 days.
Complete standardized questionnaires assessing tinnitus severity, sleep, mood, and overall improvement at baseline, Day 14, and Day 30.
Engage with the digital platform for tinnitus self-management.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study is a prospective, two-arm, parallel-group, open-label randomized controlled trial designed to evaluate the efficacy, usability, and safety of a multi-agent large language model (LLM)-based conversational artificial intelligence system (Fudan Tinnitus Doctor, FTD) for the management of chronic subjective tinnitus.
A total of 256 participants will be randomized in a 1:1 ratio to either the FTD intervention or a non-conversational digital education control. The intervention period is 30 days. The FTD system delivers personalized, real-time tinnitus management using a multi-agent architecture integrating cognitive behavioral therapy (CBT)-based strategies, including psychoeducation, cognitive restructuring, relaxation training, and sleep hygiene guidance. The control group receives a static digital program consisting of educational materials and a fixed-response question-and-answer module.
The primary outcome will be the change in tinnitus severity measured by the Tinnitus Handicap Inventory (THI) from baseline to Day 30. Secondary outcomes will include sleep quality (Pittsburgh Sleep Quality Index, PSQI), anxiety (GAD-2), depression (PHQ-2), and overall perceived improvement (Patient Global Impression of Change, PGIC). Exploratory outcomes will assess usability (System Usability Scale, SUS), satisfaction (Net Promoter Score, NPS), and engagement metrics. All outcomes will be analyzed using mixed-effects models under the intention-to-treat principle.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Shan Sun, Ph.D
- Número de teléfono: +86-021-64377134-2033
- Correo electrónico: sunshine7896@126.com
Ubicaciones de estudio
-
-
-
Shanghai, Porcelana, 200031
- Fudan University Eye Ear Nose and Throat Hospital, Otorhinolaryngology Department
-
Contacto:
- Shan Sun, Ph.D
- Número de teléfono: +86-021-64377134-2033
- Correo electrónico: sunshine7896@126.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Diagnosis of subjective tinnitus confirmed by a qualified investigator.
- Tinnitus duration ≥ 3 month prior to screening.
- THI score of ≥ 18
- Aged between 18 and 70 years
- The ability to use a smartphone: Both groups will receive therapeutic support and disease management primarily through a mobile application or web-based platform. This requires functional ability to operate the provided software and willingness to engage with the digital intervention protocol.
- Perceptibility: Tinnitus is present and recognizable by the participant under ordinary daily conditions (not only in quiet environments).
- Compliance and consent: Participant is assessed by the Investigator as able to understand study procedures, voluntarily agrees to participate, is willing to comply with all trial-related requirements, and provides signed informed consent prior to performance of any protocol-specified procedure.
Exclusion Criteria:
- Acute-phase tinnitus (duration < 3 month or tinnitus secondary to acute otologic events).
- Pulsatile or objective tinnitus.
- Unstable symptoms: Fluctuating tinnitus loudness at screening or baseline.
- Psychiatric contraindication: History or current presence of severe psychiatric disorders (e.g., major depressive disorder with recent suicidality, schizophrenia) that, in the opinion of the Investigator, may interfere with study participation or data validity.
- Testing limitations: Inability to adequately complete tinnitus testing procedures or comply with study assessments.
- Prior therapy exposure: Previous history of sound therapy specifically for tinnitus management.
- Concurrent treatments: Ongoing psychotherapy for conditions such as anxiety or depression, or any other psychological treatment that may interfere with the study endpoints.
- Concurrent trial participation: Active participation in another interventional research study that, in the opinion of the Investigator, could affect tinnitus symptoms or interact with study procedures.
- Investigator judgment: Any condition (medical, surgical, psychiatric, or social) or factor which, in the Investigator's judgment, renders the subject unsuitable for participation, places the patient at higher risk, or may interfere with compliance or scientific validity of the trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: FTD Conversational AI Intervention
Participants in this arm will use the Fudan Tinnitus Doctor (FTD) system, a multi-agent large language model-based conversational AI platform that delivers personalized tinnitus management strategies based on cognitive behavioral therapy principles.
|
The FTD system is a multi-agent conversational artificial intelligence platform that delivers personalized tinnitus management through a secure web-based interface.
It supports multimodal interaction (text and voice) and integrates a large language model, retrieval-augmented generation, and multi-agent collaboration to provide cognitive behavioral therapy-based interventions, including psychoeducation, cognitive restructuring, relaxation techniques, and sleep hygiene guidance.
|
|
Comparador activo: Digital Education Control
Participants in this arm will receive access to a non-conversational digital program consisting of static educational materials and a fixed-response question-and-answer module related to tinnitus, sleep, and mental health.
|
Participants in this arm will receive access to a non-conversational digital tinnitus self-management program delivered through the same secure web-based interface as the intervention group.
The program provides static educational materials and a fixed-response question-and-answer module related to tinnitus, sleep, and mental health.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Inventario de Discapacidad por Acúfenos (THI)
Periodo de tiempo: Línea de base, Día 14 y Día 30
|
El cuestionario THI, ampliamente utilizado en la investigación, incluye subescalas funcionales, emocionales y catastróficas.
Consta de 25 preguntas, y las respuestas se califican en una escala de "sí" (4 puntos), "a veces" (2 puntos) y "no" (0 puntos).
La puntuación total se calcula sumando las puntuaciones de todas las preguntas y clasificando la gravedad del tinnitus como: sin discapacidad (0-16), discapacidad leve (18-36), discapacidad moderada (38-56) y discapacidad grave (58-100).
|
Línea de base, Día 14 y Día 30
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cuestionario de Salud del Paciente-2 (PHQ-2)
Periodo de tiempo: Línea de base, Día 14 y Día 30
|
El PHQ-2 medirá los síntomas depresivos durante las últimas dos semanas.
Cada uno de los dos ítems se califica de 0 ("nada en absoluto") a 3 ("casi todos los días").
La puntuación total oscila entre 0 y 6, donde puntuaciones más altas indican mayores síntomas depresivos.
Una puntuación ≥3 sugiere depresión clínicamente significativa.
|
Línea de base, Día 14 y Día 30
|
|
Impresión Global del Paciente sobre el Cambio (PGIC)
Periodo de tiempo: Día 14 y día 30
|
La PGIC evaluará la percepción general del participante sobre la mejora desde que comenzó la intervención.
Se califica en una escala Likert de 7 puntos desde 1 ("muy mejorado") hasta 7 ("mucho peor"), donde las puntuaciones más bajas representan una mayor mejora percibida.
|
Día 14 y día 30
|
|
Generalized Anxiety Disorder Scale (GAD-2)
Periodo de tiempo: Baseline, Day 14, and Day 30]
|
The GAD-2 will assess anxiety symptoms over the past two weeks.
Each of the two items is rated from 0 ("not at all") to 3 ("nearly every day").
The total score ranges from 0 to 6, with higher scores indicating greater anxiety.
A score ≥3 suggests clinically significant anxiety.
|
Baseline, Day 14, and Day 30]
|
|
Pittsburgh Sleep Quality Index (PSQI)
Periodo de tiempo: Baseline, Day 14, and Day 30
|
The PSQI will be used to evaluate subjective sleep quality over the past month.
It comprises 19 items yielding seven component scores (subjective sleep quality, latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction).
The global PSQI score ranges from 0 to 21, with higher scores indicating worse sleep quality.
|
Baseline, Day 14, and Day 30
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Puntuación de Promotores Netos (NPS)
Periodo de tiempo: Día 30
|
La Puntuación Neta del Promotor (NPS) se utilizará para evaluar la probabilidad de que los participantes recomienden el sistema Fudan Tinnitus Doctor a otros en el Día 30.
Los participantes calificarán su probabilidad en una escala del 0 (nada probable) al 10 (extremadamente probable).
|
Día 30
|
|
System Usability Scale (SUS)
Periodo de tiempo: Day 30
|
The System Usability Scale (SUS) will be used to evaluate participants' perceived usability and satisfaction with the Fudan Tinnitus Doctor (FTD) conversational AI system at Day 30.
The SUS is a 10-item questionnaire rated on a 5- point scale.
The total score will be calculated as (sum of adjusted item scores × 2.5), ranging from 0 to 100, with higher scores indicating greater usability.
|
Day 30
|
|
User Engagement Metrics
Periodo de tiempo: Continuous during 30-day intervention period
|
User engagement will be assessed using three predefined system-recorded metrics: (1)Login Frequency: Number of logins. (2)Active Session Duration: Total time (minutes) spent actively interacting with the system, excluding inactive periods and time spent completing study assessments. (3)Conversation Turns: Number of complete interaction cycles, defined as one user input followed by one system response. Higher values indicate greater engagement. |
Continuous during 30-day intervention period
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Shan Sun, Eye and ENT Hospital of Fudan University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Enfermedades Otorrinolaringológicas
- Trastornos sensoriales
- Enfermedades del oído
- Trastornos de la audición
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Tinnitus
- Terapéutica
- Terapia con drogas
- Sistemas de administración de medicamentos
Otros números de identificación del estudio
- 2025072
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .